What the FDA labels say about taking them together
Ustekinumab and ustekinumab-srlf
Ustekinumab-srlf's FDA label of June 17, 2026 names ustekinumab in its contraindications section; the ustekinumab labels PlainMeds reads (4) do not name ustekinumab-srlf. The ustekinumab-srlf label: “Initiate treatment of latent TB before administering IMULDOSA. Malignancies: Ustekinumab products may increase risk of malignancy.”
Check it at the source: the ustekinumab FDA label on DailyMed (effective September 8, 2026, Janssen Biotech, Inc.); the ustekinumab-srlf FDA label on DailyMed (effective June 17, 2026).
What does the ustekinumab label say about ustekinumab-srlf?
Ustekinumab's label (effective September 8, 2026) and its 3 other brand-application labels do not name ustekinumab-srlf in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Stelara), Janssen Biotech, Inc., effective September 8, 2026 (SPL set c77a9664-e3bb-4023-b400-127aa53bca2b), via openFDA; the full label on DailyMed
What does the ustekinumab-srlf label say about ustekinumab?
Ustekinumab-srlf label, contraindicationsCONTRAINDICATIONS IMULDOSA is contraindicated in patients with clinically significant hypersensitivity to Ustekinumab products or to any of the excipients in IMULDOSA [ see Warnings and Precautions ( 5.5 ) ].
Ustekinumab-srlf label, drug interactionsUstekinumab products may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy.
Ustekinumab-srlf label, warnings and precautionsInitiate treatment of latent TB before administering IMULDOSA. ( 5.3 ) Malignancies: Ustekinumab products may increase risk of malignancy.
Source: FDA drug label (IMULDOSA), Accord BioPharma Inc., effective June 17, 2026 (SPL set 2539a6cf-0fe5-1565-e063-6294a90a3618), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ustekinumab | Ustekinumab-srlf | |
|---|---|---|
| Labeled for | Crohn's disease and ulcerative colitis | Crohn's disease and ulcerative colitis |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $29,874.45 per mL 45 mg/0.5 mL syringe | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once